8 research outputs found
Taliglucerase alfa in the longterm treatment of children and adolescents with type 1 Gaucher disease: the Albanian experience
IntroductionEnzyme replacement therapy is already recognized as the gold standard of care for patients with Gaucher disease. Taliglucerase alfa is one of the three alternatives recommended for treatment of Gaucher disease in children and adults.AimThis study aims to evaluate the long-term efficacy and safety of Taliglucerase alfa in children and adolescents with Type 1 Gaucher disease.Patients and methodsOver a six-year period, we monitored the efficacy of continuous treatment in 10 patients by assessing various parameters, including hemoglobin concentration, platelet count, liver and spleen volume, bone mineral density, glucosylsphingosine level, chitotriosidase activity, and growth parameters. Safety was evaluated by immunogenicity and adverse event monitoring.ResultsThe mean age of patients was 13.4 ± 3.6 years and the treatment duration was 60.24 ± 13.4 months. From baseline to end line the parameters change as follows: hemoglobin concentration improved from 12.7 (±1.3) to 14.6 (±1.5) and platelet count from 180 (±74) to 198 (±79). The spleen volume, was reduced by 46% (p = 0,007). The chitotriosidase activity decreased from 4,019.7 (±3,542.0) nmoles/ml/hr to 2,039.5 (±1,372.2) nmoles/ml/hr (46% reduction). Glucoylsphingosine level dropped from 119.2 (±70.4) ng/ml to 86.2 (±38.1) ng/ml, indicating a reduction of 28%. Bone mineral density Z-score, improved from −1.47 (±1.76) to −0.46 (±0.99) (69.7% reduction). Out of the 1,301 total administrations, our patients reported only 37 (2.8%) infusion-related adverse events which were mild and transitory.ConclusionTaliglucerase alfa exhibits good efficacy and a safe profile in the treatment of children and adolescents with Type 1 Gaucher disease
Religion in census, the 2011 Albania experience and its flaws
The sensitive topic of religion in the Albanian 2011 census and the coming one is the focus of this study. The country majority is composed of ethnic Albanians, sharing the same nationality; blood, language, culture, territory while religion differs. It was found a flaw in categorization under the category ‘Bektashi’, one of the Albanian traditional divisions historically a sub-category of ‘Islam’. Placing it as a separate category, while the main body category ‘Islam’ is the other option creates fogginess for the inquired person. Checking on ‘Islam’ excludes s/he from the possibility to choose ‘Bektashi’ and vice versa. Data retrieved from the official INSTAT Albania online web atlas and reorganized second study objectives. Maps show a shift from traditional religious categories, Muslim, Catholic, Orthodox and Bektashi with clear geographical connotations. Traditional religious nominations range from the lowest loss of 2.9% to 56.5%. With a range 53.6%, and mean and standard deviation 23.6±13.3%, change is statistically significant p<0.001. The whole country records a fidelity to traditional categories of 75.6%. The quest of separation from the main body of a religious affiliation is a special case of separation because the sub-division always pretends to save the original message, not bringing a novelty. The case of the Albanian religious census categories superposition constitutes a technical error that needs revision
Predictors of esophageal varices and first variceal bleeding in liver cirrhosis patients
Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC)
Background: Parenchymal changes after stereotactic body radiation therapy (SBRT) make differential diagnosis between treatment outcomes and disease recurrence often difficult. The purpose of our study was to identify the radiographic features detectable at computed tomography (CT) scan [high-risk features (HRFs)] that allow enough specificity and sensitivity for early detection of recurrence. Methods: We retrospectively evaluated patients who underwent SBRT for inoperable early stage nonsmall cell lung cancer (NSCLC). The median delivered dose performed was 50 Gy in 5 fractions prescribed to 80% isodose. All patients underwent chest CT scan before SBRT and at 3, 6, 12, 18, 24 months after, and then annually. Each CT scan was evaluated and benign and HRFs were recorded.18F-fluorodeoxyglucose- CT was not used routinely. Results: Forty-five patients were included (34 males, 11 females; median age: 77 years; stage IA: 77.8%, stage IB: 22.2%; median follow-up: 21.7 months). Two year and actuarial local control was 77%. HRFs were identified in 20 patients. The most significant predictor of relapse was an enlarging opacity at 12 months (P 2 HRFs
Two cases of imported hemorrhagic fever with renal syndrome and systematic review of literature
Unveiling the incidences and trends of the neglected zoonosis cystic echinococcosis in Europe: a systematic review from the MEmE project
ReviewThe neglected zoonosis cystic echinococcosis affects mainly pastoral and rural communities in both low-income and upper-middle-income countries. In Europe, it should be regarded as an orphan and rare disease. Although human cystic echinococcosis is a notifiable parasitic infectious disease in most European countries, in practice it is largely under-reported by national health systems. To fill this gap, we extracted data on the number, incidence, and trend of human cases in Europe through a systematic review approach, using both the scientific and grey literature and accounting for the period of publication from 1997 to 2021. The highest number of possible human cases at the national level was calculated from various data sources to generate a descriptive model of human cystic echinococcosis in Europe. We identified 64 745 human cystic echinococcosis cases from 40 European countries. The mean annual incidence from 1997 to 2020 throughout Europe was 0·64 cases per 100 000 people and in EU member states was 0·50 cases per 100 000 people. Based on incidence rates and trends detected in this study, the current epicentre of cystic echinococcosis in Europe is in the southeastern European countries, whereas historical endemic European Mediterranean countries have recorded a decrease in the number of cases over the time.Key messages: - This study aims to shed light on the unrecognised incidence of cystic echinococcosis in Europe, unveiling its epidemiological effect by providing a quantitative measure of number, incidence, and trends of human cases documented within the period 1997–2021; - Since human cystic echinococcosis cases are generally under-reported and data have uncertainty (partly due to misdiagnosis), data provided in this study should be considered as a conservative estimate of the real impact of this zoonotic infection historically occurring in Europe; - For the years 2017–19, we identified a total number of cystic echinococcosis cases four-fold higher than for The European Surveillance System (TESSy) data; - Decreasing trends have been recorded in most southern Mediterranean and some eastern European countries, where cystic echinococcosis has traditionally been highly prevalent; - Increasing trends have been identified in some eastern and southeastern European countries but, unexpectedly, also in most non-endemic countries of northern and western Europe; - Based on incidence and trends from 2017–19, the current epicentre of cystic echinococcosis in Europe is represented by the Balkan Peninsula; - Cystic echinococcosis in Europe remains a relevant public health issue and findings from this study should be used to support the planning of surveillance and control programmes in Europe according to the WHO 2021–2030 roadmap for neglected tropical diseases.This research was funded by the MEmE project from the EU’s Horizon
2020 Research and Innovation programme under grant agreement
number 773830: One Health European Joint Programme. This work was
also partially supported by research funding (grant PRG1209) from the
Estonian Ministry of Education and Researchinfo:eu-repo/semantics/publishedVersio
Unveiling the incidences and trends of the neglected zoonosis cystic echinococcosis in Europe: a systematic review from the MEmE project.
The neglected zoonosis cystic echinococcosis affects mainly pastoral and rural communities in both low-income and upper-middle-income countries. In Europe, it should be regarded as an orphan and rare disease. Although human cystic echinococcosis is a notifiable parasitic infectious disease in most European countries, in practice it is largely under-reported by national health systems. To fill this gap, we extracted data on the number, incidence, and trend of human cases in Europe through a systematic review approach, using both the scientific and grey literature and accounting for the period of publication from 1997 to 2021. The highest number of possible human cases at the national level was calculated from various data sources to generate a descriptive model of human cystic echinococcosis in Europe. We identified 64 745 human cystic echinococcosis cases from 40 European countries. The mean annual incidence from 1997 to 2020 throughout Europe was 0·64 cases per 100 000 people and in EU member states was 0·50 cases per 100 000 people. Based on incidence rates and trends detected in this study, the current epicentre of cystic echinococcosis in Europe is in the southeastern European countries, whereas historical endemic European Mediterranean countries have recorded a decrease in the number of cases over the time